ERBB3 and cancer: There are essentially two reasons behind this therapeutic strategy: first, HER-3 is overexpressed in many cancers [5]; second, the receptor acts as the main hub for escape mechanisms during the emergence of resistance to anticancer drugs [22,23,24].